Krystal Biotech KRYS 深 沪
已收盘 09-19 16:00:00 美东时间
163.57
+2.960
+1.84%
华盛通- 最 高168.42
- 今 开161.91
- 成交量 81.10万股
- 最 低 160.4968
- 昨 收 160.61
- 总市值 47.27亿
- 52周最高 207.84
- 市盈率 静 54.56
- 换手率 0.00%
- 52周最低 122.80
- 委 比 -61.84%
- 总股本 2889.87万
- 历史最高 219.34
- 量 比 1.84
- 振 幅 4.93%
- 历史最低 8.03
- 每 手 1
- 风险率 33.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Krystal Biotech gets expanded FDA approval for Vyjuvek
Krystal Biotech (NASDAQ:KRYS) announced that the FDA has approved an updated label for its gene therapy, Vyjuvek (beremagene geperpavec). The new approval broadens the patient eligibility for Vyjuvek ...
09-15 23:58
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
The U.S. FDA has updated the label for VYJUVEK, allowing its use for dystrophic epidermolysis bullosa (DEB) patients from birth and enabling patients and caregivers to apply the treatment at home. The update also increases flexibility in wound dressing management, improving convenience without compromising safety. Based on real-world data and studies, the changes reinforce VYJUVEK's role as a flexible and effective gene therapy for DEB, addressin...
09-15 12:00
Krystal Integrated Services Ltd. Expands with New Subsidiary in Port Services
Krystal Integrated Services Ltd. ( ($IN:KRYSTAL) ) has provided an announcement...
09-07 17:14
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
Krystal Biotech (NASDAQ: KRYS) announced its participation in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishnan, the Company’s Chairman and CEO, will engage in a fireside chat at 10:20 am ET and host investor meetings. A webcast of the presentation will be available starting at 10:20 am ET on September 4 and posted on the Investors section of the Company’s website. Krystal Biotech is a global biotec...
09-02 12:00
A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts
10 analysts have shared their evaluations of Krystal Biotech (NASDAQ:KRYS) duri...
08-23 03:00
Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent
Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell l...
08-22 00:59
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years...
08-18 22:15
美股大行评级 | 潜在涨幅345.51%！BTIG上调Syndax Pharmaceuticals目标价至56美元，维持"买入"评级
今日重点评级关注：BTIG：维持Syndax Pharmaceuticals"买入"评级，目标价从43美元升至56美元；花旗：维持Syndax Pharmaceuticals"买入"评级，目标价从46美元升至51美元
08-06 09:30
Citigroup Maintains Neutral on Krystal Biotech, Lowers Price Target to $166
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Neutral and lowers the price target from $176 to $166.
08-06 01:52
What 8 Analyst Ratings Have To Say About Krystal Biotech
In the preceding three months, 8 analysts have released ratings for Krystal Bio...
08-05 22:02
